Browsing Tag
ARCH Venture Partners
3 posts
Why Seaport’s U.S. IPO filing matters now for neuropsychiatric drug development and biotech capital markets
Seaport Therapeutics has filed for a U.S. IPO. Read how its neuropsychiatry pipeline could test biotech investor appetite in 2026.
Can Harbor Health’s Rippl deal redefine dementia care economics in Texas and beyond?
Harbor Health acquires Rippl to expand dementia care and strengthen its pay-vider model. Discover what this means for Texas healthcare markets.
US neurobehavioral health company BlackThorn raises $76m to advance AI-driven targeted therapeutics
California-based neurobehavioral health company BlackThorn Therapeutics has raised $76 million through a Series B financing round to advance…